Breast Cancer

Articles

Register for CancerNetwork's live, interactive event featuring leaders in oncology reviewing and discussing patient cases in breast cancer.

Around the Practice: January 2021 Virtual Tumor Board

ARX788 received a nod from the FDA early in 2021 based on promising preclinical and phase 1 trial data demonstrating its efficacy in patients with HER2-positive breast cancer following progression on other agents. 

FDA Action Moves ARX788 Forward in the Treatment of HER2-Positive Breast Cancer

The FDA approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least 1 of which was for metastatic disease.

FDA Approves Margetuximab-cmkb, Chemo Combo for Pretreated Metastatic HER2+ Breast Cancer

Impressive signals of efficacy, durable responses, overall survival rates, and a tolerable safety profile were all found for fam-trastuzumab deruxtecan-nxki to treat patients with HER2-positive metastatic breast cancer.

Impressive Efficacy Reported for Trastuzumab Deruxtecan to Treat HER2+ Metastatic Breast Cancer

The combination use of neoadjuvant paclitaxel, trastuzumab, and pertuzumab followed by adjuvant trastuzumab for patients with pathologic complete response or followed by adjuvant dose-dense anthracycline/cyclophosphamide plus T-DM1 for patients with residual disease offered the highest health benefits and lowest costs.

Study Identifies Cost-Effective Strategies for Neoadjuvant-Adjuvant Treatment of HER2-Positive Breast Cancer

Investigators suggested that guidelines which recommend initiating screening mammography at age 50 may be putting Black women at a disadvantage, and screening should thus begin by age 40.

Researchers Suggest Breast Cancer Screening in Black Women be Initiated by Age 40

The DESTINY-Breast05 trial will investigate fam-trastuzumab deruxtecan-nxki (Enhertu) versus ado-trastuzumab emtansine (T-DM1) as adjuvant therapy in patients with HER2-positive early breast cancer who have a high risk of disease recurrence and residual invasive disease in the breast or axillary lymph nodes after receiving neoadjuvant therapy.

Phase 3 Study To Evaluate Fam-trastuzumab Deruxtecan-nxki in HER2+ Early Breast Cancer

A study which evaluated lapatinib (Tykerb) and trastuzumab (Herceptin) given prior to surgery in patients with early HER2-positive breast cancer revealed that women who had a pathological complete response survived longer without the cancer returning than those who did not.

Study Finds Patients with HER2+ Breast Cancer Live Longer if Anti-Cancer Drugs Induce pCR

Videos

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

Gregory Vidal, MD, PhD, on Treating Patients with HER2+ Breast Cancer During COVID-19

The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.

HER2-Positive Breast Cancer | Topics